Sign in

    Jingming Chen • Evercore ISI

    Jingming Chen is an Equity Research Analyst at Evercore ISI focused on biotechnology, frequently engaging in research and earnings calls for companies such as Travere Therapeutics and Innate Pharma. Chen contributes research coverage and analysis for clinical-stage biopharmaceutical firms, providing market insights and forecasts for investors and clients. While performance metrics such as TipRanks rankings or success rates are not publicly available, Chen has participated in key sector earnings calls and research commentary since at least early 2023. Chen holds a research analyst role and specializes in biotechnology and pharmaceutical company coverage, though specific professional credentials and securities licenses are not disclosed in publicly available sources.

    Jingming Chen's questions to Editas Medicine Inc (EDIT) leadership

    Jingming Chen's questions to Editas Medicine Inc (EDIT) leadership • Q2 2024

    Question

    Jingming Chen, on for Liisa Bayko, asked how Editas plans to target the large patient population in the Middle East, questioning if they would launch themselves or seek a partner.

    Answer

    Chief Commercial and Strategy Officer Caren Deardorf acknowledged the significant unmet need in the Middle East and other geographies. She reiterated the company's strategy to 'consider partnering for anything outside of the United States' to accelerate patient access to therapies like reni-cel.

    Ask Fintool Equity Research AI

    Jingming Chen's questions to Innate Pharma SA (IPHA) leadership

    Jingming Chen's questions to Innate Pharma SA (IPHA) leadership • Q2 2023

    Question

    The analyst asked about the timing and venue for the upcoming lacutamab data release and the subsequent regulatory and development strategy for the drug in CTCL, including potential filing plans.

    Answer

    The company will present lacutamab data at a medical conference in H2 2023 once an abstract is accepted. The next steps involve discussions with the FDA to finalize Phase 3 plans based on the new data, while also actively exploring partnerships to maximize the asset's value and guide later-stage development.

    Ask Fintool Equity Research AI